Search

Displaying results 141 - 150 of 6090 in total
  1. Drug

    Von Willebrand factor human

    go.drugbank.com/drugs/DB13133
    ApprovedInvestigational

    The human von Willebrand factor (vWF) is a human plasma-derived vWF, an endogenous large multimeric plasma glycoprotein involved in hemostasis. It serves a dual role in hemostasis by mediating platelet adhesion and aggregation at the sit...

    Mixtures: Haemate P Powder and solvent for solution for injection or infusion, Haemate P 1000IU Powder and solvent for solution for injection or infusionProducts: IMMUNATE 50 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION, IMMUNATE 100 IU/ML POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
  2. Drug

    Piperacillin

    go.drugbank.com/drugs/DB00319
    ApprovedInvestigational

    Semisynthetic, broad-spectrum, ampicillin derived ureidopenicillin antibiotic proposed for pseudomonas infections. It is also used in combination with other antibiotics.

    Mixtures: PIPTAZ-AFT POWDER FOR SOLUTION FOR INJECTION 4.5G/VIAL, SALATAZ POWDER FOR SOLUTION FOR INJECTION/INFUSION 4.5G/VIALCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  3. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    It was first approved in China in December 2018 for the treatment of unresectable or metastatic melanoma in previously treated patients. … [A262011,A262591] Toripalimab was granted FDA approval in October 2023 for the treatment of select patients with nasopharyngeal carcinomas.[L48696]

    Products: TUOYI (toripalimab) 240mg/6ml (40mg/ml) Concentrate for Solution for Infusion
  4. Drug

    Trastuzumab deruxtecan

    go.drugbank.com/drugs/DB14962
    ApprovedInvestigational

    Trastuzumab deruxtecan is a HER2-directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of treatment-resistant HER2-positive cancers.

    Products: ENHERTU POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/VIAL, Enhertu Powder For Concentrate For Solution For Infusion 100 mg/vial
  5. Drug

    Siltuximab

    go.drugbank.com/drugs/DB09036
    ApprovedInvestigational

    Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

    Products: Sylvant 400mg Powder for Concentrate for Solution for Infusion, Sylvant 100mg Powder for Concentrate for Solution for Infusion
  6. Drug

    Mosunetuzumab

    go.drugbank.com/drugs/DB15434
    ApprovedInvestigational

    [L44562] and in December 2025, the subcutaneous formulation was approved for the same indication. [L54848] … [A249320] The standard of care for patients with B-cell lymphoma includes an anti-CD20 monoclonal antibody, such as [rituximab], in combination with chemotherapy.

    Products: Lunsumio 1mg/ml Concentrate for Solution for Infusion
  7. Drug

    Acetazolamide

    go.drugbank.com/drugs/DB00819
    ApprovedInvestigationalVet approved

    One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizur...

    Products: DIAMOX Sodium 500mg Powder for Solution for Injection, Acetazolamide 500mg Powder for Solution for Injection
  8. Drug

    Inotuzumab ozogamicin

    go.drugbank.com/drugs/DB05889
    ApprovedInvestigational

    [A20352] Inotuzumab ozogamicin was first approved by the European Commission in June 2017 for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

    Products: BESPONSA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 1MG/VIAL
  9. Drug

    Thyrotropin alfa

    go.drugbank.com/drugs/DB00024
    ApprovedInvestigationalVet approved

    The alpha subunit of thyrotropin alfa, which is the effector region responsible for the stimulation of adenylate cyclase, displays close structural similarity with the alpha subunit of human chorionic

    Products: Thyrogen 0.9 mg Powder for Solution for Injection
  10. Drug

    Idarucizumab

    go.drugbank.com/drugs/DB09264
    Approved

    Approved under the tradename Praxbind (FDA), idarucizumab is indicated for the emergency treatment of dabigatran-associated bleeding in life-threatening or surgically induced situations.

    Products: PRAXBIND SOLUTION FOR INJECTION/INFUSION 50 MG/ML, PRAXBIND Solution for Injection/Infusion 50 mg/ml